论文部分内容阅读
目的:探讨131I-Herceptin对HER2过表达乳腺癌细胞Bcl-x L表达的影响。方法:采用Iodogen法制备131I-Herceptin,超滤法纯化后测定其标记率、放射化学纯度和免疫结合率。通过免疫荧光法检测乳腺癌细胞表面HER2表达水平。131I(4.625 MBq/m L)、Herceptin(125μg/m L)及131I-Herceptin(4.625 MBq/m L)干预乳腺癌BT474细胞后,Western blot检测细胞中Bcl-x L的表达。结果:131I-Herceptin的标记率、放射化学纯度和免疫结合率分别为(89.71±2.93)%、(91.80±1.43)%和(58.84±3.35)%。BT474细胞膜表面HER2表达水平明显高于MDA-MB-231细胞。Herceptin、131I-Herceptin组BT474细胞内Bcl-x L表达水平明显低于对照组及131I组(均P<0.01),而Herceptin与131I-Herceptin组之间细胞内Bcl-x L含量差异无统计学意义(P>0.05)。结论:131I-Herceptin保留Herceptin对HER2过表达乳腺癌细胞Bcl-x L表达的抑制作用并促进细胞凋亡,进而与131I产生协同作用,较Herceptin更有效地杀伤HER2过表达乳腺癌细胞。
Objective: To investigate the effect of 131I-Herceptin on the expression of Bcl-xL in HER2 overexpressing breast cancer cells. Methods: 131I-Herceptin was prepared by Iodogen method. After purification, the labeling rate, radiochemical purity and immunological binding rate were determined. HER2 expression on breast cancer cells was detected by immunofluorescence. Western blot was used to detect the expression of Bcl-x L in cells after intervention with 131I (4.625 MBq / m L), Herceptin (125μg / m L) and 131I-Herceptin (4.625 MBq / m L) Results: The labeling rate, radiochemical purity and immunological binding rate of 131I-Herceptin were (89.71 ± 2.93)%, (91.80 ± 1.43)% and (58.84 ± 3.35)%, respectively. The level of HER2 expression on BT474 cell membrane was significantly higher than that of MDA-MB-231 cells. Herceptin, 131I-Herceptin group BT474 cells Bcl-xL expression was significantly lower than the control group and 131I group (all P <0.01), while the Herceptin and 131I-Herceptin group Bcl-xL content between the no significant difference Significance (P> 0.05). Conclusion: 131I-Herceptin preserves Herceptin on HER2 overexpression in breast cancer Bcl-xL expression and promote apoptosis, and then synergistic with 131I, Herceptin more effective than HER2 overexpression of breast cancer cells.